Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - bortezomib 2.5mg (as a mannitol boronic ester) - powder for injection - 2.5 mg - active: bortezomib 2.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - bortezomib 3.5mg (as a mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol - bortezomib sandoz, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib sandoz, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib sandoz is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib sandoz in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Singapore - engleză - HSA (Health Sciences Authority)

pfizer private limited - bortezomib (as a mannitol boronic ester) - injection, powder, for solution - bortezomib (as a mannitol boronic ester) 3.50mg

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

biotech pharma limited - bortezomib - powder for solution for injection - 3.5 milligram(s) - bortezomib

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

european regulatory affairs t/a ivowen - bortezomib - powder for solution for injection - 2.5 milligram(s) - bortezomib

Malta - engleză - Medicines Authority

clonmel healthcare limited waterford road, clonmel, co. tipperary e91 d768, ireland - bortezomib - solution for injection - bortezomib 3.5 mg - antineoplastic agents

Malta - engleză - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - bortezomib - powder for solution for injection - bortezomib 3.5 mg - antineoplastic agents

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

msn labs europe limited - bortezomib - powder for solution for injection - bortezomib

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - bortezomib - powder for solution for injection - bortezomib